Cybele Ghossein, MD
Nephrology · Chicago, ILNPI 1376588830
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,478 of the $23,234 with a category attached, or 66.6%. Amgen accounts for 98.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $6,484 and has fallen 92.3% since, to $500 in 2025. Among nephrology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 30 payments — averaging $774.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$23K
- Calliditas Therapeutics US Inc.$205
- Apellis Pharmaceuticals, Inc.$161
- Vertex$73
Across 102 payments — averaging $3678.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$255K
- Travere Therapeutics, Inc.$82K
- Vertex$39K
What the payments were for
- Consulting fees$5,38123%
- Speaking & faculty fees$15,47867%
- Travel & lodging$1,2465%
- Food & beverage$1,1305%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 26 | $22,796 |
| Calliditas Therapeutics US Inc. | 2 | $205 |
| Apellis Pharmaceuticals, Inc. | 1 | $161 |
| Vertex | 1 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,234 in reported general payments places this provider in the 90th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 52 | $41,814 |
| Tacrolimus | 29 | $11,215 |
| Mycophenolate Mofetil | 33 | $1,645 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,174 |
| Losartan Potassium | 70 | $858 |
| Lisinopril | 56 | $649 |
| Gabapentin | 22 | $552 |
| Torsemide | 39 | $515 |
| Allopurinol | 26 | $293 |
| Prednisone | 17 | $273 |
| Atorvastatin Calcium | 18 | $241 |
| Furosemide | 18 | $229 |
| Carvedilol | 26 | $188 |
| Amlodipine Besylate | 35 | $164 |
| Spironolactone | 16 | $133 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Chicago
- Myles WolfChicago$2.1M
- Susan QuagginChicago$262K
- Nicole StankusChicago$235K
- Marco BonillaChicago$148K
- Lorenzo GallonChicago$120K
- Vikram AggarwalChicago$117K
- Jay KoynerChicago$113K
- Jose ArrudaChicago$107K
- John FriedewaldChicago$93K
- Casey GashtiChicago$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.